Looking for CJC-1295 DAC peptide for sale for laboratory research? PX1 Research supplies USA-synthesized CJC-1295 with Drug Affinity Complex (DAC) featuring verified purity above 99% by RP-HPLC and mass spectrometry. Every lot undergoes rigorous third-party testing to ensure analytical precision in preclinical growth factor assays.
Looking for CJC-1295 DAC peptide for sale for laboratory research? PX1 Research supplies USA-synthesized CJC-1295 with Drug Affinity Complex (DAC) featuring verified purity above 99% by RP-HPLC and mass spectrometry. Every lot undergoes rigorous third-party testing to ensure analytical precision in preclinical growth factor assays.
When purchasing CJC-1295 DAC for experimental protocols, research institutions and analytical laboratories require rigorous quality control, verified sequence identity, and consistent lot-to-lot purity. CJC-1295 DAC peptide is a synthetic 30-amino acid analog of Growth Hormone-Releasing Hormone (GHRH) modified with a Drug Affinity Complex (DAC) reactive group. This specific chemical modification enables covalent binding to endogenous serum albumin, dramatically extending its biological half-life in animal models compared to native GHRH.
Investigators evaluating growth hormone secretagogue pathways depend on chemical integrity to prevent confounding data. Low-grade peptides containing TFA residues, truncated sequence fragments, or bacterial endotoxins compromise receptor binding assays and cellular proliferation studies. PX1 Research delivers laboratory-grade reagents produced in USA-based, GMP-compliant facilities, backed by comprehensive analytical documentation accessible through our expanded catalog of research peptides.
Native GHRH (1-29) possesses a rapid biological clearance profile, with an in vivo half-life measured in minutes due to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). To overcome this kinetic limitation in longitudinal studies, scientists engineered CJC-1295 with the inclusion of a maleimido derivative attached to the C-terminal lysine residue. This structural moiety constitutes the Drug Affinity Complex (DAC).
Upon administration in preclinical animal models, the maleimide group forms a stable covalent bond with the free thiol group of Lys-34 on serum albumin. This bioconjugation shields the peptide backbone from DPP-IV degradation and renal filtration. As detailed in our growth hormone secretagogues overview, this modification extends the terminal half-life of the compound to several days in rodent and non-human primate models, allowing researchers to study sustained GHRH signaling without requiring constant infusion protocols.
CJC-1295 DAC functions as a selective agonist at the GHRH receptor located on somatotroph cells within the anterior pituitary gland. Ligand binding activates the G-protein coupled receptor (GPCR) cascade, stimulating adenylate cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP). This intracellular signaling cascade drives the transcription and exocytosis of growth hormone (GH).
Unlike short-acting secretagogues that induce transient GH spikes, preclinical models demonstrate that CJC-1295 DAC establishes a elevated baseline of growth hormone release while preserving the physiological pulsatility of the pituitary gland. The continuous GH elevation subsequently stimulates hepatic synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1), providing a stable endocrine model to investigate downstream cellular targets.
In vitro assays and rodent studies actively utilize CJC-1295 DAC to examine tissue repair pathways, protein synthesis rates, and body composition dynamics. Because growth hormone and IGF-1 modulate collagen deposition, chondrocyte proliferation, and skeletal muscle cell hypertrophy, researchers utilize this long-acting GHRH analog to explore accelerated wound healing and extracellular matrix deposition.
Preclinical data indicate that sustained IGF-1 elevation induced by CJC-1295 DAC accelerates myoblast differentiation and enhances nitrogen retention in rodent models of muscular atrophy. Furthermore, metabolic studies suggest that continuous GHRH receptor stimulation influences lipid metabolism by upregulating lipolysis in adipocytes and enhancing fatty acid oxidation during metabolic stress assays. Scientists interested in cross-referencing these signaling cascades can review detailed study profiles in the PX1 research library hub.
Understanding the differences among GHRH analogs and growth hormone secretagogues is critical when designing cell culture or animal research protocols. CJC-1295 DAC offers an extended half-life through covalent albumin binding, whereas CJC-1295 No DAC lacks the maleimido linker, resulting in a significantly shorter duration of action (half-life of ~30 minutes vs ~6-8 days in rodent models). For researchers examining short-burst pulsatile GH release, modified GHRH derivatives like Sermorelin present alternative kinetics.
When evaluating synergistic pituitary stimulation, investigators frequently compare GHRH receptor agonists with Growth Hormone Secretagogue Receptor (GHSR) agonists. Dual-receptor research designs often combine GHRH analogs with selective ghrelin mimetics such as Ipamorelin or GHRP-2 to analyze additive GH release dynamics. A comprehensive head-to-head analysis of these pharmacokinetics is available in our technical report on CJC-1295 DAC vs No DAC.
To guarantee reproducible laboratory outcomes, research compounds must meet rigorous purity criteria. At PX1 Research, every batch of CJC-1295 DAC undergoes independent third-party verification performed by ISO 17025 accredited analytical laboratories. We supply comprehensive Certificates of Analysis (COAs) with every order, detailing lot-specific chromatographic and spectroscopic data.
Purity is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), confirming a chemical purity profile of ≥99%. Mass Spectrometry (MS) is utilized to confirm exact molecular weight and amino acid sequence fidelity, ruling out truncated peptides or synthesis impurities. Additionally, every lot undergoes chromogenic LAL assay testing to confirm endotoxin levels remain strictly below <0.01 EU/mg, protecting cell cultures and animal models from inflammatory interference.
Proper reconstitution technique is essential to maintain the structural integrity of lyophilized CJC-1295 DAC. Research peptides are sensitive to mechanical agitation, temperature fluctuations, and pH variations. When reconstituting in a laboratory environment, technicians should adhere to standardized sterile handling procedures within a laminar flow hood.
Bacteriostatic water (0.9% benzyl alcohol preserved) or sterile deionized water should be introduced slowly along the glass wall of the vial to allow passive dissolution without violent shaking. Shaking or vortexing can cause peptide aggregation and denaturation. Once fully reconstituted, volumetric calculations should be documented based on the exact lyophilized mass (e.g., 2mg or 5mg vial) to ensure precise concentration tracking in subsequent assay dilutions.
Lyophilized CJC-1295 DAC exhibits superior thermal stability when stored under controlled conditions. Upon arrival at the laboratory, sealed lyophilized vials should be stored in a sub-zero freezer at -20°C or -80°C for long-term storage, shielded from light exposure. Under these conditions, the peptide remains stable for up to 24 months without measurable degradation.
Reconstituted solutions are significantly more susceptible to enzymatic degradation and hydrolysis. Fluid aliquots should be maintained at 2°C to 8°C and used within 14 to 28 days depending on the reconstitution medium. For extended experimental timelines, reconstituted solutions should be aliquoted into single-use microcentrifuge tubes and frozen at -80°C to eliminate repeated freeze-thaw cycles, which degrade peptide purity.
PX1 Research serves as a trusted domestic supply partner for academic institutions, biotechnology research organizations, and contract research organizations (CROs). We maintain an uninterrupted inventory of USA-synthesized research peptides to support continuous, large-scale longitudinal studies.
All orders ship directly from our state-of-the-art storage facilities in California and Arizona, utilizing expedited handling to minimize transit exposure. Principal investigators and laboratory managers managing multi-phase research projects can explore bulk procurement pathways and custom synthesis requirements through our wholesale research program.
What is the primary difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a Drug Affinity Complex (maleimido moiety) that allows it to covalently bind to serum albumin in vivo, extending its biological half-life to several days in animal models. CJC-1295 No DAC lacks this group and exhibits a half-life of approximately 30 minutes.
How is the purity of CJC-1295 DAC verified at PX1 Research?
Purity is verified through third-party ISO 17025 laboratory testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure ≥99% purity, alongside Mass Spectrometry (MS) for sequence verification and chromogenic LAL assays for endotoxin quantification.
What is the target receptor for CJC-1295 DAC in preclinical research?
CJC-1295 DAC is a selective agonist of the Growth Hormone-Releasing Hormone (GHRH) receptor located on somatotroph cells in the anterior pituitary gland.
What diluent should be used to reconstitute CJC-1295 DAC for laboratory assays?
Sterile bacteriostatic water (containing 0.9% benzyl alcohol) is typically used for multi-dose laboratory sampling, while sterile physiological saline or pure water for injection may be used for immediate single-use cell culture assays.
How should lyophilized CJC-1295 DAC be stored upon receipt?
Unopened lyophilized vials should be stored at -20°C or -80°C in a dry environment protected from light. Under sub-zero storage, the compound remains stable for up to 24 months.
What are the published endotoxin limits for PX1 Research peptides?
Every lot of CJC-1295 DAC is tested to ensure bacterial endotoxin levels remain below <0.01 EU/mg, preventing baseline cellular toxicity or inflammatory signaling in downstream applications.
Is CJC-1295 DAC approved for human consumption or therapeutic use?
No. CJC-1295 DAC supplied by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical animal research) and is not for human or veterinary medical use.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are synthesized in USA-based, GMP-compliant facilities and shipped directly from fulfillment centers located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.